Warnex Inc.

Warnex Inc.

October 06, 2005 07:00 ET

Warnex signs up major poultry producer, Marshall Durbin

LAVAL, QC, Oct. 6 - Warnex Inc. (TSX:WNX) announced today it has
signed up Marshall Durbin, one of the largest privately owned poultry
companies in the United States, as a customer of the Warnex™ Rapid Pathogen
Detection System. After having performed a thorough evaluation of the Warnex
system, Marshall Durbin has acquired the Warnex system to monitor the safety
of its products.

Based in Birmingham, Alabama, Marshall Durbin is a leading manufacturer
of chicken products employing more than 1850 employees and producing over
350,000,000 pounds of chicken per year. The company is vertically integrated,
complete with its own hatcheries, breeder flocks, contract growers, processing
plants, feed mills, and distribution facilities.

The Warnex Rapid Pathogen Detection System uses cutting-edge DNA-based
technology to rapidly and accurately determine the presence of pathogens in a
food sample. The system allows for the simultaneous detection of multiple
pathogens and processing of samples within 12 to 48 hours, a significant
improvement over traditional microbiology tests that currently require 5 to 7

About Warnex

Warnex (www.warnex.ca) is a publicly traded (TSX: WNX) Canadian
biotechnology company devoted to protecting public health by providing
advanced diagnostic and quality control products and services to the
pharmaceutical, agri-food, and healthcare sectors. Warnex's genomics-based
technology offers a versatile detection platform that produces accurate
results rapidly, using Real-Time PCR technology combined with unique genetic
markers and software. Applications range from pathogen detection in foods and
GMO testing to farm-to-fork traceability using Molecular Bar Codes. Our
development pipeline includes applications in the detection of viruses,
toxins, yeasts, and fungi, as well as meat speciation and bioterrorism.
Warnex's profitable and growing analytical, bioanalytical, and clinical
service groups offer a variety of quality control services, method development
and validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.


Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, such as market
conditions, currency, technological, financial, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to Warnex's
Annual Report under the heading Risks and Uncertainties in the Management's
Discussion and Analysis section. Consequently, actual results may differ
materially from the anticipated results expressed in these forward-looking
statements. Warnex disclaims any intention or obligation to update any
forward-looking statements, whether as a result of new information or

Contact Information